CONCLUSION
To our knowledge, this is the first case report about Dolutegravir
causing acquired sideroblastic anemia. Even though Dolutegravir is a new
antiretroviral drug with effective virologic suppression, good
tolerability, infrequent drug-drug interactions, and once-daily
administration, patients might be experiencing certain side effects like
sideroblastic anemia. Early recognition and prompt management of such
issues is a must since it might impact drug compliance and ultimately
the quality of life. The majority of individuals with anemia who are
treated in primary care clinics are thought to have iron deficiency
anemia, which is more frequent. Clinicians must, however, be aware of
the potential for sideroblastic anemia. To properly manage the patient,
the primary care physician, nurse practitioner, and internist must be
able to identify and diagnose this illness. To assess the prognosis and
epidemiology of this condition, more clinical research is also required.